Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02628067
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:17.368083+00:00
Published At
2025-09-22T00:00:00+00:00
Record Updated At
2025-09-22
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Advanced Cancer", "Anal Carcinoma", "Anal Cancer", "Biliary Cancer", "Cholangiocarcinoma", "Bile Duct Cancer", "Neuroendocrine Tumor", "Carcinoid Tumor", "Endometrial Carcinoma", "Endometrial Cancer", "Cervical Carcinoma", "Cervical Cancer", "Vulvar Carcinoma", "Vulvar Cancer", "Small Cell Lung Carcinoma", "Small Cell Lung Cancer (SCLC)", "Mesothelioma", "Thyroid Carcinoma", "Thyroid Cancer", "Salivary Gland Carcinoma", "Salivary Gland Cancer", "Salivary Cancer", "Parotid Gland Cancer", "Advanced Solid Tumors", "Colorectal Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-09-22"
protocolSection.identificationModule.nctId
"NCT02628067"
protocolSection.identificationModule.officialTitle
"A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Advanced Cancer (protocolSection.conditionsModule.conditions)
  • Anal Carcinoma (protocolSection.conditionsModule.conditions)
  • Anal Cancer (protocolSection.conditionsModule.conditions)
  • Biliary Cancer (protocolSection.conditionsModule.conditions)
  • Cholangiocarcinoma (protocolSection.conditionsModule.conditions)
  • Bile Duct Cancer (protocolSection.conditionsModule.conditions)
  • Neuroendocrine Tumor (protocolSection.conditionsModule.conditions)
  • Carcinoid Tumor (protocolSection.conditionsModule.conditions)
  • Endometrial Carcinoma (protocolSection.conditionsModule.conditions)
  • Endometrial Cancer (protocolSection.conditionsModule.conditions)
  • Cervical Carcinoma (protocolSection.conditionsModule.conditions)
  • Cervical Cancer (protocolSection.conditionsModule.conditions)
  • Vulvar Carcinoma (protocolSection.conditionsModule.conditions)
  • Vulvar Cancer (protocolSection.conditionsModule.conditions)
  • Small Cell Lung Carcinoma (protocolSection.conditionsModule.conditions)
  • Small Cell Lung Cancer (SCLC) (protocolSection.conditionsModule.conditions)
  • Mesothelioma (protocolSection.conditionsModule.conditions)
  • Thyroid Carcinoma (protocolSection.conditionsModule.conditions)
  • Thyroid Cancer (protocolSection.conditionsModule.conditions)
  • Salivary Gland Carcinoma (protocolSection.conditionsModule.conditions)
  • Salivary Gland Cancer (protocolSection.conditionsModule.conditions)
  • Salivary Cancer (protocolSection.conditionsModule.conditions)
  • Parotid Gland Cancer (protocolSection.conditionsModule.conditions)
  • Advanced Solid Tumors (protocolSection.conditionsModule.conditions)
  • Colorectal Carcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.